Leflunomide: A novel disease modifying anti-rheumatic drug

Journal of Postgraduate Medicine

Volumn 50, Issue 2, 2004, Pages 154-157

  Kale, Vijay P ^a   Bichile, L S ^a  

^a KEM HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ANTIRHEUMATIC AGENT; COLESTYRAMINE; DIHYDROOROTATE DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; PYRIMIDINE; RIFAMPICIN; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE; TRANSFORMING GROWTH FACTOR BETA;

ABDOMINAL PAIN; ALOPECIA; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BACKACHE; BODY WEIGHT DISORDER; BRONCHITIS; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG STRUCTURE; DYSPEPSIA; ERYTHEMA MULTIFORME; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFECTION; INTERSTITIAL LUNG DISEASE; JOINT INJURY; LEUKOPENIA; LIVER DYSFUNCTION; MOUTH ULCER; MYALGIA; NAUSEA; PANCYTOPENIA; PROTEIN SYNTHESIS INHIBITION; RASH; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; STEVENS JOHNSON SYNDROME; STRUCTURE ANALYSIS; TENOSYNOVITIS; TERATOGENESIS; TOXIC EPIDERMAL NECROLYSIS; URINARY TRACT INFECTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; DRUG INTERACTIONS; HUMANS; ISOXAZOLES; MOLECULAR STRUCTURE;

EID: 4043114982     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989;16:585-91.
2. Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996;39:713-22.
3. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000;59:841-9
4. Prakash A, Jarvis B. Leflunomide- A review of its use in active Rheumatoid arthritis. Drugs 1999;58:1137-64
5. Siemasko KF, Chong ASF, Williams JW, Bremer EG, Finnegan A. Regulation of B cell function by the immunsuppressive agent leflunomide. Transplantation 1996;61:635-42
6. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 1999;162:2095-102.
7. Hamilton LC, Vojnovic I, Marner TD. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. Br J Pharmacol 1999;127:1589-96.
8. Arava (Leflunomide) Prescribing Information as of September 2003. Aventis Pharmaceuticals Inc. Kansas City, MO 64137
9. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1995;38:1595-603.
10. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G. et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-50.
11. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000;39:655-65.
12. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. Two-year. blinded, randomised, controlled trial of treatment of rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001;44:1984-92.
13. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentric trial. Lancet 1999;353:259-66.
14. Scott DL, Smolen JS, Kalden JR, Van de Putte LB, Larsen A, Kvien TK, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow-up of a double-blind, placebo controlled trial versus sulphasalazine. Ann Rheum Dis 2001;60:913-23.
15. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, et al. Leflunomide for the treatment of rheumatoid arthritis: A systematic review and meta-analysis. J Rheumatol 2003;30:1182-90.
16. Kremer JM, Genovese MC, Cannon GW, Caldwell JR. Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137:726-33.
17. Kalden JR, Schattenkirchner M, Sorensen H, Emery P, Deighton C, Rozman B, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year follow-up study. Arthritis Rheum 2003;48:1513-20.
18. Rozman B, Praprotnik D, Logar D, Tomsic M, Hojnik M, Kos-Golja M, et al. Leflunomide and hypertension. Ann Rheum Dis 2002;61:567-9.
19. Fischer TW, Bauer HI, Graefe T, Barta U, Elsner P. Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide. Dermatology 2003;207:386-9.
20. Jakez-Ocampo, Richaud-Patin Y, Granados J, Sanchez-Guerrero J, Llorente L, Weekly leflunomide as monotherapy for recent-onset rheumatoid arthritis. Arthritis Rheum 2004;51:147-8.
21. Jaimes-Hernandez J, Robles- San Roman M, Suarez-Otero R, Daval Zugasti ME, Arroyo-Borrego S. Rheumatoid arthritis treatment with weekly leflunomide: an open-label study. J Rheumatol 2004;31:235-7.
22. Harris ED, Jr. Treatment of Rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB. eds, Kelly's Textbook of Rheumatology. 6th ed, W B Saunders Company, 2000:p-1017.
23. Breedveld FC. Is there a place for leflunomide in the treatment of rheumatoid arthritis? Lancet 2001;358:1198-200.
24. Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus:a pilot observational study. Lupus 2001;10:480-3.
25. Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 2004;43:315-20.
26. Prajapati DN, Knox JF, Emmons J, Saeian K, Csuka ME, Binion DG. Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy. J Clin Gastroenterol 2003;37:125-8.
27. Eckhardt SG, Rizzo J, Sweeney KR, Cropp G, Baker SD, Kraynak MA, et al. Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 (Leflunomide) in patients with advanced solid tumours. Clin Oncol 1999;17:1095-104.